Zobrazeno 1 - 10
of 301
pro vyhledávání: '"Santiago Ponce"'
Autor:
Rafal Dziadziuszko, Nir Peled, Tony Mok, Solange Peters, Santiago Ponce Aix, Jorge Alatorre-Alexander, Brian D. Vicuna, Margaret Maclennan, Vijay Bhagawati-Prasad, Sarah M. Shagan, Erica Schleifman, Thorsten Ruf, Michael S. Mathisen, Shirish M. Gadgeel
Publikováno v:
Contemporary Oncology, Vol 27, Iss 4, Pp 217-223 (2024)
Externí odkaz:
https://doaj.org/article/de66fd03358a49bbbdeaeff487884027
Autor:
Damien Vasseur, Ahmadreza Arbab, Fabiola Giudici, Christophe Marzac, Stefan Michiels, Marco Tagliamento, Arnaud Bayle, Cristina Smolenschi, Madona Sakkal, Mihaela Aldea, Hela Sassi, Filippo Gustavo Dall’Olio, Noémie Pata-Merci, Sophie Cotteret, Alice Fiévet, Nathalie Auger, Luc Friboulet, Francesco Facchinetti, Arthur Géraud, Santiago Ponce, Antoine Hollebecque, Benjamin Besse, Jean Baptiste Micol, Antoine Italiano, Ludovic Lacroix, Etienne Rouleau
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-10 (2024)
Abstract Next-generation sequencing (NGS) assays based on plasma cell-free DNA (cfDNA) are increasingly used for clinical trials inclusion. Their optimized limit of detection applied to a large number of genes leads to the identification of mutations
Externí odkaz:
https://doaj.org/article/4130073b97594d488656afc4bdbd62db
Autor:
Stephane Champiat, Francois-Xavier Danlos, Aurélien Marabelle, Yohann Loriot, Julia Delahousse, Kaïssa Ouali, Santiago Ponce, Laurent Mathiot, David Combarel, Justin Cagnat, Sophie Broutin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 5 (2024)
Patients with advanced cancer, previously treated with immune checkpoint blockade therapy, may retain residual treatment when undergoing the initial infusion of experimental monotherapy in phase 1 clinical trials. ANV419, an antibody-cytokine fusion
Externí odkaz:
https://doaj.org/article/5bfb019c346a4f1aac8465d84d118e78
Autor:
Ernest Nadal, Mansoor Saleh, Santiago Ponce Aix, Maria Ochoa-de-Olza, Sandip Pravin Patel, Scott Antonia, Yumin Zhao, Ivelina Gueorguieva, Michael Man, Shawn T. Estrem, Jiangang Liu, Emin Avsar, Wen Hong Lin, Karim A. Benhadji, Leena Gandhi, Susan C. Guba, Inmaculada Ales Diaz
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-13 (2023)
Abstract Background In this phase Ib/II open-label study, tumor immune suppression was targeted in patients with advanced refractory solid tumors and patients with recurrent/refractory non-small cell lung cancer (NSCLC) using galunisertib with nivolu
Externí odkaz:
https://doaj.org/article/f152b1db103e441ba5117026cc7aba88
Autor:
Daneng Li, Yohann Loriot, Adam M. Burgoyne, James M. Cleary, Armando Santoro, Daniel Lin, Santiago Ponce Aix, Ignacio Garrido-Laguna, Ramu Sudhagoni, Xiang Guo, Svetlana Andrianova, Scott Paulson
Publikováno v:
EClinicalMedicine, Vol 67, Iss , Pp 102376- (2024)
Summary: Background: Cabozantinib is approved for previously treated advanced hepatocellular carcinoma (aHCC) and has been investigated in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJ). Atezolizumab plus bevacizumab is approv
Externí odkaz:
https://doaj.org/article/4755d3d913804c63b46661b4dce5ecba
Autor:
Magnus Jaderberg, Victor Levitsky, Luis Paz-Ares, Nicolas Isambert, Susana Cedres, Xavier Serres, Charles Ricordel, Sylvia Vetrhus, Alex Martinez-Marti, Santiago Viteri, Alejandro Navarro, Jon Zugazagoitia, Santiago Ponce, Mercedes Herrera-Juarez, Mathieu Lederlin, Thomas Birkballe Hansen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 9 (2023)
Background ONCOS-102, an oncolytic adenovirus expressing granulocyte-macrophage colony-stimulating factor, can alter the tumor microenvironment to an immunostimulatory state. Combining ONCOS-102 with standard-of-care chemotherapy for malignant pleura
Externí odkaz:
https://doaj.org/article/948af889fc44483eac5e19bcc3f77280
Autor:
Zoran Andric, MD, Gabriella Gálffy, MD, Manuel Cobo Dols, MD, Barna Szima, MD, Goran Stojanovic, MD, Marina Petrovic, MD, Enriqueta Felip, MD, David Vicente Baz, MD, Santiago Ponce Aix, MD, Oscar Juan-Vidal, MD, Zsuzsanna Szalai, MD, Gyorgy Losonczy, MD, Antonio Calles Blanco, MD, Reyes Bernabe, MD, Gema García Ledo, MD, Andrés Aguilar Hernández, MD, Klaus Duecker, PhD, Dongli Zhou, PhD, Andreas Schroeder, MD, Guelseren Guezel, MD, Fortunato Ciardiello, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 2, Pp 100461- (2023)
Introduction: We present the results of a phase 2a trial of first-line avelumab (anti–programmed death-ligand 1 antibody) plus cetuximab (anti–EGFR antibody) in patients with advanced squamous NSCLC. Methods: Patients with recurrent or metastatic
Externí odkaz:
https://doaj.org/article/283d0b24db6b460b8d6628f029ba7cc0
Autor:
Tala Tayoun, Vincent Faugeroux, Marianne Oulhen, Olivier Déas, Judith Michels, Laura Brulle-Soumare, Stefano Cairo, Jean-Yves Scoazec, Virginie Marty, Agathe Aberlenc, David Planchard, Jordi Remon, Santiago Ponce, Benjamin Besse, Patricia L. Kannouche, Jean-Gabriel Judde, Patrycja Pawlikowska, Françoise Farace
Publikováno v:
JCI Insight, Vol 7, Iss 11 (2022)
DNA damage and genomic instability contribute to non–small cell lung cancer (NSCLC) etiology and progression. However, their therapeutic exploitation is disappointing. CTC-derived explants (CDX) offer systems for mechanistic investigation of CTC me
Externí odkaz:
https://doaj.org/article/e641159387994f2a91ffabd1b17d0b73
Autor:
Juan Moreno-Rubio, Santiago Ponce, Rosa Álvarez, María Eugenia Olmedo, Sandra Falagan, Xabier Mielgo, Fátima Navarro, Patricia Cruz, Luis Cabezón-Gutiérrez, Carlos Aguado, Gonzalo Colmenarejo, Marta Muñoz-Fernández de Leglaria, Ana Belén Enguita, María Cebollero, Amparo Benito, Isabel Alemany, Carolina del Castillo, Ricardo Ramos, Ana Ramírez de Molina, Enrique Casado, Maria Sereno
Publikováno v:
Cancer Biology & Medicine, Vol 17, Iss 2, Pp 444-457 (2020)
Objective: Long-term survivors (LS) of non-small cell lung cancer (NSCLC) without driver alterations, displaying an overall survival (OS) of more than 3 years, comprise around 10% of cases in several series treated with chemotherapy. There are classi
Externí odkaz:
https://doaj.org/article/36439633311a4ff2ae4cf60b69f45489
Autor:
Edurne Arriola, MD, PhD, José Manuel Trigo, MD, Amparo Sánchez-Gastaldo, MD, Alejandro Navarro, MD, Coral Perez, MD, Leonardo Crama, MD, Santiago Ponce-Aix, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 1, Pp 100266- (2022)
Introduction: SCLC is one of the most lethal malignancies. Classically, staging has been performed using a dual classification distinguishing limited from the extensive stage. This study aimed to evaluate the prognostic value of TNM staging in a real
Externí odkaz:
https://doaj.org/article/ee4d170a7bb04b6b9b63698467121349